-
公开(公告)号:US10975120B2
公开(公告)日:2021-04-13
申请号:US16204557
申请日:2018-11-29
Applicant: Novartis AG
Inventor: Aimee Richardson Usera , Zachary Hayes Robinson , Jennifer Stroka Cobb
IPC: C07K5/103 , C07K5/083 , C07K5/062 , A61K49/00 , C07C271/22 , C07C317/28 , C07K1/13 , C07K5/072 , A61K47/64 , C07D229/02 , C07D257/08 , C07D209/42 , C07K7/02 , A61K38/06 , A61K38/05 , A61K38/07 , A61K38/00
Abstract: The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses.
-
公开(公告)号:US20240216513A1
公开(公告)日:2024-07-04
申请号:US18281732
申请日:2022-03-10
Applicant: Novartis AG
Inventor: Claire Adcock , Valerie Broennimann , Jiashun Cheng , Rohit Kumar Duvadie , Tanzina Fazal , Jinhai Gao , Fengfeng Guo , Robert Martin Grotzfeld , Christina Hebach , Gregory John Hollingworth , Darryl Brynley Jones , Alexei Karpov , Jialiang Li , Julien Lorber , Chester A. Metcalf, III , Walter Michael , Mark Gabriel Palermo , Scott Vaughan Plummer , James Harold Roache , Martin Sendzik , Ranny Mathew Thomas , Aimee Richardson Usera , Anna Vulpetti , Frederic Zecri , Liang Zhao , Thomas Zoller
IPC: A61K47/54 , A61K31/395 , A61K47/10 , A61P35/00
CPC classification number: A61K47/542 , A61K31/395 , A61K47/10 , A61P35/00
Abstract: Described herein are fatty acid-bifunctional degrader compounds, their various targets, their preparation, pharmaceutical compositions comprising them, and their use in the treatment of conditions, diseases, and disorders mediated by various target proteins.
-
公开(公告)号:US10786576B2
公开(公告)日:2020-09-29
申请号:US15985060
申请日:2018-05-21
Applicant: NOVARTIS AG
Inventor: Alexandra Marshall Bruce , Aaron Kanter , Changgang Lou , Aimee Richardson Usera , Jun Yuan , Frederic Zecri
IPC: A61K47/54 , A61K38/095 , A61K38/08 , A61K38/16 , A61K38/17 , A61K38/18 , A61K38/22 , A61K45/06 , C07C55/02 , C07C55/22 , C07C57/02 , C07C57/18 , C07C59/245 , C12N15/113
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号:US10588980B2
公开(公告)日:2020-03-17
申请号:US14738272
申请日:2015-06-12
Applicant: Novartis AG
Inventor: Alexandra Marshall Bruce , Aimee Richardson Usera , Frederic Zecri , Jun Yuan , Changgang Lou , Aaron Kanter
IPC: A61K47/54 , A61K38/08 , A61K38/16 , A61K38/17 , A61K38/18 , A61K38/22 , A61K45/06 , C07C55/02 , C07C55/22 , C07C57/02 , C07C57/18 , C07C59/245 , C12N15/113
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3: wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
公开(公告)号:US11752211B2
公开(公告)日:2023-09-12
申请号:US16889201
申请日:2020-06-01
Applicant: NOVARTIS AG
Inventor: Alexandra Marshall Bruce , Aaron Kanter , Aimee Richardson Usera , Jun Yuan , Frederic Zecri
IPC: A61K47/54 , A61K38/095 , A61K38/16 , A61K38/17 , A61K38/18 , A61K38/22 , A61K45/06 , C07C55/02 , C07C55/22 , C07C57/02 , C07C57/18 , C07C59/245 , C12N15/113
CPC classification number: A61K47/543 , A61K38/095 , A61K38/164 , A61K38/1709 , A61K38/1825 , A61K38/1841 , A61K38/2221 , A61K45/06 , A61K47/542 , C07C55/02 , C07C55/22 , C07C57/02 , C07C57/18 , C07C59/245 , C12N15/113 , C12N2310/14 , C12N2310/351
Abstract: The invention provides a conjugate comprising a biomolecule linked to a fatty acid via a linker wherein the fatty acid has the following Formulae A1, A2 or A3:
wherein R1, R2, R3, R4, Ak, n, m and p are defined herein. The invention also relates to a method for manufacturing the conjugate of the invention such as GDF15 conjugate, and its therapeutic uses such as treatment or prevention of metabolic disorders or diseases, type 2 diabetes mellitus, obesity, pancreatitis, dyslipidemia, alcoholic and nonalcoholic fatty liver disease/steatohepatitis and other progressive liver diseases, insulin resistance, hyperinsulinemia, glucose intolerance, hyperglycemia, metabolic syndrome, hypertension, cardiovascular disease, atherosclerosis, peripheral arterial disease, stroke, heart failure, coronary heart disease, diabetic complications (including but not limited to chronic kidney disease), neuropathy, gastroparesis and other metabolic disorders. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.-
公开(公告)号:US20190300570A1
公开(公告)日:2019-10-03
申请号:US16204557
申请日:2018-11-29
Applicant: Novartis AG
Inventor: Aimee Richardson Usera , Zachary Hayes Robinson , Jennifer Stroka Cobb
IPC: C07K5/103 , C07K5/072 , C07C271/22 , C07C317/28 , C07D229/02 , C07D257/08 , A61K49/00 , A61K47/64 , C07K1/13 , C07K5/062 , C07K5/083
Abstract: The present invention relates to methods and reagents for use in site-selective modification of proteins having lysine residues with functionalized peptides using a chemoenzymatic microbial transglutaminase-mediated reaction. The functionalized proteins may be used for study or therapeutic uses.
-
公开(公告)号:US09931372B2
公开(公告)日:2018-04-03
申请号:US14996418
申请日:2016-01-15
Applicant: Novartis AG
Inventor: Aaron Kanter , Aimee Richardson Usera , Frederic Zecri
CPC classification number: A61K38/12 , A61K45/06 , A61K47/542 , A61K47/60 , A61K47/64 , A61K51/0402 , C07K7/64 , C07K14/47
Abstract: The invention provides a conjugate, or a pharmaceutically acceptable salt thereof, comprising a synthetic polypeptide of Formula I: Q-R-P-R-L-C*-H-K-G-P-(Nle)-C*-F (I) or a amide or ester thereof; and a fatty acid selected from: wherein said fatty acid is covalently linked to the N-terminus of the peptide via one of its carboxylic acid functionality, optionally via a polyethylene glycol linker; and wherein the two cysteine amino acids labeled with “*” form a disulfide bond between the thiol functionalities of their side chain. The conjugates are agonist of the APJ receptor. The invention also relates to a method for manufacturing the conjugates of the invention, and its therapeutic uses such as treatment or prevention of acute decompensated heart failure (ADHF), chronic heart failure, pulmonary hypertension, atrial fibrillation, Brugada syndrome, ventricular tachycardia, atherosclerosis, hypertension, restenosis, ischemic cardiovascular diseases, cardiomyopathy, cardiac fibrosis, arrhythmia, water retention, diabetes (including gestational diabetes), obesity, peripheral arterial disease, cerebrovascular accidents, transient ischemic attacks, traumatic brain injuries, amyotrophic lateral sclerosis, burn injuries (including sunburn) and preeclampsia. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
-
-
-
-
-
-